𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)

✍ Scribed by T. Kühr; S. Burgstaller; U. Apfelbeck; W. Linkesch; H. Seewann; M. Fridrik; G. Michlmayr; O. Krieger; D. Lutz; W. Lin; J. Pont; L. Köck; K. Abbrederis; C. Baldinger; R. Buder; D. Geissler; H. Hausmaninger; A. Lang; A. Zabernigg; C. Duba; W. Hilbe; W. Eisterer; M. Fiegl; R. Greil; G. Gastl; J. Thaler

Book ID
108403260
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
269 KB
Volume
27
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of imatinib versus in
Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment